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Symptomatic venous thromboembolism after
femoral vein harvest
Ravi V. Dhanisetty, MD,a Timothy K. Liem, MD,a Gregory J. Landry, MD,a Brett C. Sheppard, MD,b
Erica L. Mitchell, MD,a and Gregory L. Moneta, MD,a Portland, Ore
Objective: The femoral vein is increasingly utilized as a conduit in major arterial and venous reconstruction. However,
perioperative complications, especially venous thromboembolism (VTE) associated with femoral vein harvest (FVH), are
not well described. The purpose of this study was to determine the incidence and risk factors for the development of
symptomatic VTE in patients who undergo FVH.
Methods: We conducted a retrospective cohort study of all patients who underwent FVH over a 5-year period at a single
institution. Patient clinical characteristics, indications for surgery, postoperative venous duplex scans, and computerized
tomography scans of the chest were gathered and reviewed from an electronic medical record query. Statistical analysis
was performed to determine which factors correlate with development of perioperative complications after FVH.
Results: There were 57 patients (53% male; mean age, 62 years) who underwent 58 FVHs. Of the procedures, 53% were
performed for arterial reconstruction and 47% for vascular reconstruction after cancer resection (85% portomesenteric
reconstruction). Perioperative VTEs were diagnosed in 17 of 58 (29%) FVH procedures. Sixteen ipsilateral deep vein
thromboses (DVTs) occurred distal to the FVH site and five (9%) occurred proximal to the FVH site. The incidence of
VTE was significantly greater in patients with malignancy (52% vs 10%; P .001), and 88% of all VTEs in this series were
diagnosed in patients with cancer. All DVTs proximal to the FVH site and all DVTs in the contralateral extremity
occurred in patients with malignancy. Pulmonary embolism occurred in two patients. No patients developed compart-
ment syndrome or limb loss. Eight patients (14%) required FVH site wound debridement.
Conclusions:VTE after FVH occurs more frequently in patients with malignancy. Aggressive and prolonged thrombopro-
phylaxis and routine venous ultrasound surveillance are warranted after FVH in patients with malignancy. (J Vasc Surg
2012;56:696-702.)
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AThe femoral vein has been utilized as a conduit for
vascular reconstruction dating back to 1981.1 Initial re-
ports regarding use of femoral vein as a conduit described
complications that included postoperative phlegmasia re-
quiring fasciotomy, vein bypass, and even amputation.2 In
contrast, Clagett’s later reports described a larger number
of patients who underwent femoral vein harvest (FVH) for
arterial reconstruction with minimal long-term venous
morbidity.3,4 Subsequently, the safety of FVH, along with
the excellent patency rates, have been documented in mul-
tiple reports.5-7 These reports led to greater acceptance and
wider usage of the femoral vein as a durable autogenous
arterial conduit and as a venous conduit as well.8
In previous studies, however, femoral vein was used
mainly for aortoiliac reconstruction and femoral-femoral
bypass. There have been limited reports regarding the
venous morbidity after FVH in a wider variety of patients,
especially those with cancer. The purpose of this study was
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696o determine the incidence of perioperative complications
ssociated with FVH procedures, and to determine if any
linical or technical factors were related to such complica-
ions.
ETHODS
This study was approved by the Institutional Review
oard at Oregon Health and Science University. We retro-
pectively identified all patients who underwent FVH pro-
edures at Oregon Health and Science University between
anuary 2005 and February 2011 using current procedural
erminology code of 35572, “Harvest of fem-pop vein.”
ifty-seven such patients who underwent 58 FVH proce-
ures for arterial and venous reconstructions were identi-
ed.
Electronic medical records, laboratory reports, and ra-
iology reports for each of the identified patients were then
eviewed. Patient demographics, common atherosclerotic
nd venous thrombotic risk factors, and preoperative labo-
atory variables were collected. These included age, gender,
ody mass index (BMI), hypertension, diabetes mellitus,
ypercholesterolemia, past history of venous thromboem-
olism (VTE), arrhythmias, renal insufficiency or failure,
moking history, and an identified hypercoagulable state.
hese variables were identified by physician documentation
r by active use of medications for any of these conditions.
one of the patients in our study were on dialysis. Renal
nsufficiency was defined as serum creatinine1.5 mg/dL.
lso, the indication for FVH, operative reports, and hospi-al course, including timing of VTE prophylaxis, and in-
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Volume 56, Number 3 Dhanisetty et al 697hospital complications requiring reoperation or extended
stay in the intensive care unit were determined. Timing and
results of vascular laboratory studies, including periopera-
tive venous duplex ultrasound examinations and computed
tomography (CT) scans of the chest performed in the
perioperative period, were recorded.
Primary end points of symptomatic VTE and FVH
wound complications were recorded. There was no screen-
ing program for deep vein thrombosis (DVT) in FVH
patients at our institution during the study period. All
venous duplex ultrasound examinations were performed
for symptoms or suspicion of VTE and were performed
bilaterally per protocol. CT scans of chest were done for
patient symptoms or clinical suspicion of VTE. Any VTE
diagnosed within 30 days after the vein harvest procedure
was recorded as a primary end point. An FVH wound
complication was defined as any complication of the wound
that required additional care due to a surgical site infection,
wound dehiscence, or persistent drainage.
Statistical analysis using SPSS version 20.0 (Chicago,
Ill) was performed to delineate which patient factors corre-
lated with development of either of the primary end points.
The study population was divided into two groups based on
development of either of the primary end points. Patient
characteristics and comorbidities were then compared be-
tween the groups. 2 test was used to compare categorical
variables. For categorical variables with less than five cases,
Fisher exact test was used. Categorical variables are re-
ported as frequency observed (percentage). Independent
variable t-test was used to compare continuous variables
between the patient groups. All continuous variables like
age, BMI, albumin, and postoperative DVT prophylaxis
days were uniformly distributed without any significantly
outlying values. Continuous variables are reported as
mean  standard deviation (range). For all analyses, a P
value of  .05 was considered significant. Due to the
limited number of events in the study, a multivariate anal-
ysis was not conducted.
FVH procedures were performed in a manner similar to
that described by Clagett and associates.3 In brief, bilateral
duplex ultrasound vein mapping was performed routinely
prior to the procedure to evaluate the diameter and wall
characteristics of the femoral veins. During the procedure,
the sartorius muscle was mobilized medially for exposure.
The precise caudad extent of FVH was not routinely re-
corded. However, for venous reconstructions, the length
of the harvested femoral vein segment was typically
limited to an appropriate length segment of femoral vein
in the proximal thigh. For arterial reconstructions other
than those for mesenteric ischemia, a longer segment of
femoral vein, potentially including the above-knee pop-
liteal vein segment, was frequently required. There were
no instances where vein distal to the medial epicondyle of
the femur was harvested. The junction between the
profunda femoris vein and the common femoral vein was
always preserved, with the femoral vein oversewn as close
as practical to the femoral vein/profunda femoris vein
junction. When feasible, the distal femoral vein ligation oas performed proximal to a large vein branch to main-
ain inflow from the lower leg and to try and avoid a blind
nding segment.
Closed suction drains were placed in the FVH site in all
ases. Drains were removed when the output was 30 mL
ver 24 hours. All patients were started on prophylactic
oses of low-molecular-weight heparin (LMWH) as soon
s the attending surgeon determined bleeding risks were
inimal. For patients on therapeutic anticoagulation prior
o the procedure, therapeutic doses of unfractionated hep-
rin were given. Sequential lower extremity compression
evices (SCDs) were routinely used in all patients. Com-
ression therapy (Circ Aid, San Diego, Calif) and elevation
ere also used to decrease leg edema in the harvested limb.
ilateral lower extremity venous duplex ultrasound scans
ere performed in patients with clinical suspicion of DVT
nd not for screening purposes.
ESULTS
There were 57 patients who underwent a total of 58
VHs with or without popliteal vein. (One patient had
arvest of bilateral femoral veins 4 years apart with each vein
sed as an individual conduit to treat arterial infection.)
he mean age of the cohort was 62.2  12.6 years (range,
4-86 years), and 53% were male. Indications for FVH
ncluded vascular graft infection (23/58; 40%), mesenteric
ypass (8/58; 14%), and vascular reconstruction in the
etting of surgical excision of pancreatic or head and neck
ancer (27/58; 46%). Of the 27 vascular reconstructions
erformed in the setting of cancer, 23 were for venous
econstruction to facilitate pancreatic resection and four
ere for arterial reconstruction after resection of a head and
eck malignancy. The most common comorbid conditions
ncluded hypertension (43%), smoking (38%), diabetes
ellitus (22%), need for chronic anticoagulation (16%),
nd atrial fibrillation (14%). Other conditions, including a
nown hypercoagulable state (3%) and renal insufficiency
5%), were less common. The average BMI of the patient
ohort was 25.7  5.8 (range, 15.5-43.8) and the average
reoperative albumin was 2.8  0.8 g/dL (range, 1.4-4.2
/dL). Most patients (84%) received postoperative phar-
acologic VTE prophylaxis with LMWH within the first 3
ays after the index surgical procedure, with a range of 1 to
2 days.
Overall, 36 of 57 (62%) patients received a postopera-
ive venous duplex examination for suspicion of DVT. A
T angiogram was performed for symptoms concerning
or pulmonary embolism in two patients. VTE was noted in
7 cases (29%). DVTs were detected in 16 cases and
ulmonary embolism (PE) without lower extremity DVT
n one case. When DVT was found ipsilateral to the har-
ested femoral vein, it was distal to the harvest site in all 16
ases (100%) and both proximal and distal to the harvest
ite in five of the 16 cases of DVT (31%). There were no
nstances of DVT proximal to the harvest site without DVT
istal to the harvest site. Of the 16 DVTs found distal to the
arvested vein segment, four were isolated to distal femoral
r popliteal vein segments, and four were isolated to tibial
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September 2012698 Dhanisetty et alor soleal veins. Eight cases involved a distal femoral or
popliteal vein segment and one or more tibial veins. VTE
occurred in 14 of 27 (52%) patients with cancer, compared
with three of 31 (10%) patients without a concurrent
diagnosis of cancer (Fig 1). All five cases of DVT proximal
to the femoral vein harvest site occurred in patients with
malignancy. In patients with DVT in the limb with the
FVH, there were three cases of DVT also diagnosed in the
contralateral limb. All of these patients also had a concur-
rent diagnosis of cancer. In fact, 88% of all VTEs were
diagnosed in patients with cancer. Most of these VTEs
(59%) were diagnosed in the first postoperative week (Fig
2), but a significant portion, 41%, were diagnosed 2 to 4
weeks after the index procedure.
There were no cases of DVT in patients who were
receiving therapeutic anticoagulation (16%) prior to and
after surgery. Indications for chronic anticoagulation in
these patients included atrial fibrillation, a known hyperco-
agulable state, or a past history of VTE. In all cases, thera-
peutic anticoagulation was started by the third postopera-
tive day. Both atrial fibrillation and chronic anticoagulation
were significantly associated with freedom from VTE.
Other comorbid conditions were also evaluated, and none
correlated with perioperative VTE (Table I).
Perioperative PE was diagnosed in two (3%) patients.
One of these patients underwent portomesenteric venous
reconstruction during pancreatic resection for cancer. She
was a nonsmoker but was morbidly obese with a BMI of
Fig 1. Incidence of any venous thromboembolism (V
respect to the harvested femoral vein segment in patient
VTE was statistically significant between the two group
harvest site in patients without cancer. FVH, Femoral ve43.8. The PE occurred despite VTE prophylaxis with SCDs and LMWH starting on postoperative day 1. It was diag-
osed with a CT angiogram of the chest, performed for
ever on postoperative day 14. A venous duplex scan also
howed DVT proximal and distal to the FVH site. The
econd patient with PE was a 70-year-old male who under-
ent arterial reconstruction for infection. A CT scan of the
hest, performed as an outpatient on postoperative day 29
or shortness of breath, identified the PE. This patient had
remote history of a bladder cancer that was resected 12
ears prior to his admission. In this case, SCDs and early
mbulation had been used for perioperative VTE prophy-
axis, and there was no clinical suspicion of DVT prior to
ischarge.
FVH wound complications occurred in 11 (19%) of
8 procedures. Of the 11 FVH wound complications,
ight required operative debridement. Surgical drains
emained in the FVH wounds for an average of 10 days
range, 3-34 days). Therapeutic anticoagulation did not
ffect the average time to drain removal: average of 10
ays in both groups. These values were widely distrib-
ted (postoperative days 3-34). Two of the nine patients
eceiving therapeutic anticoagulation had postoperative
ound complications requiring debridement. In all of
hese patients, the indication for debridement was super-
cial wound breakdown or an undrained seroma. None
equired operative exploration for bleeding or large he-
atoma. The only clinical variable that correlated with
he development of a wound complication was patient
nd the location of deep vein thrombosis (DVT) with
and without cancer. The difference in the incidence of
.001. There were no DVTs proximal to femoral vein
rvest.TE) a
s with
s, P ge. The average age of patients with FVH wound compli-
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Volume 56, Number 3 Dhanisetty et al 699cation was 69.3 years versus 60.5 years in patients without
wound complications (P  .038) The other clinical vari-
ables analyzed had no correlation with wound infection or
dehiscence (Table II).
DISCUSSION
Femoral vein is a reliable conduit for major arterial and
venous reconstruction and has excellent patency rates3,7,9
As a replacement for the aorta and iliac arteries, the 5-year
patency of femoral vein grafts is80%. For femoral-femoral
Fig 2. Day of diagnosis of postoperative venous thromb
(FVH) and the index procedure. Most cases of symptom
procedure. DVT, Deep vein thrombosis.
Table I. Symptomatic venous thromboembolism (VTE)
Variables VTE (
Cancer (n  27)a 14
Ageb 63.2  8.1
Male gendera 9
Side of FVH (number of left)a 11
History of smokinga 7
Hypertensiona 8
Diabetes mellitusa 3
History of VTEc
Hypercoagulable statec
Atrial fibrillationc
Chronic renal insufficiencyc
Major postoperative complicationa 8
On anticoagulation prior to procedurec
Body mass indexb 25  6.6
Postoperative VTE prophylaxis dayb 3  3.6
FVH, Femoral vein harvest.
Continuous variablesb are expressed as mean standard deviation (range). P
and 2 analysisa or Fisher exact testc was used for categorical variables.bypass, the reported patency rate is about 76%.6,7 When bsed as an arterial substitute, there have been no reported
ases of femoral vein infection, graft disruption, or aneurys-
al dilation. For major venous reconstruction, our experi-
nce with portomesenteric venous reconstruction demon-
trated patency rates of 88%.8
In addition to the excellent long-term patency results,
VH has been associated with surprisingly minimal long-
erm morbidity in the harvested limb.4 Wells et al published
he largest experience of patients who underwent FVH,
rimarily for aortoiliac reconstruction and femoral-femoral
olism (VTE). Day zero is the day of femoral vein harvest
TE (59%) were diagnosed within the first week after the
7) No VTE (n  41) P value
13 (31%) .001
75) 61.8  14.2 (24-86) .57
22 (54%) .59
26 (63%) .59
15 (37%) .48
17 (41%) .46
10 (24%) .74
2 (5%) .5
2 (5%) .5
8 (20%) .05
3 (7%) .35
13 (32%) .38
9 (22%) .03
8-43.8) 26  5.4 (15.5-38.3) .58
2) 2.3  2.0 (1-10) .60
s were obtained using independent variable t-test for continuous variablesboemb
atic Vn  1
(88%)
(48-
(44%)
(72%)
(41%)
(47%)
(18%)
0
0
0
0
(47%)
0
(18.
(1-1
valueypass. In that study, less than one-third of patients had
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September 2012700 Dhanisetty et allong-term edema without skin changes (CEAP classifica-
tion of C3). No patients had major venous insufficiency,
ulceration, or venous claudication.
Despite these favorable longer-term reports, little is
known about the short-term morbidity of FVH proce-
dures. Clagett and associates reported a 15% incidence of
DVT after FVH for aortoiliac reconstruction.3 In a follow-up
report with a larger group of patients, the incidence of DVT
increased to 22%.4 In our series, the overall incidence of
VTE was 29%, higher than previously reported. This may
be explained by the differences in study populations, as 43%
of patients in this series had vascular reconstruction with
femoral vein as part of a surgical resection for malignancy,
usually pancreatic cancer. In this series, all patients with
DVT had thrombosis distal to the harvest site. This result
was consistent with previous reports, where 84% of all
DVTs were distal to the FVH site.4
FVH in the setting of a surgical resection for cancer seems
to place the patient at increased risk for DVT. Clearly, we do
not know the incidence of DVT in a comparable control
group of patients with cancer undergoing surgical resection
without FVH. However, the incidence of symptomatic DVT
in the patients undergoing FVH in the setting of cancer was
five times higher than in those treated for other conditions
requiring FVH. This high rate of VTE occurred despite ag-
gressive postoperative mechanical and pharmacologic VTE
prophylaxis. All patients received sequential compressive de-
vices during and after the operation, and most (70%) re-
ceived prophylactic doses of LMWH by postoperative day 2.
In our cohort, all five cases of DVT proximal to the FVH site
and three cases of DVT in the contralateral extremity were
diagnosed in patients with cancer.
VTE occurred both early and late in the cancer patients.
The high rate of diagnosis of VTE after FVH in patients
with cancer well after the immediate postoperative period
would argue for prolonged VTE prophylaxis in the cancer
patients after FVH procedure. However, most of the VTEs
Table II. Wound complications
Variables Wound complica
Cancera 4 (36
Ageb 69.3  6.1 (60
Male gendera 6 (54
Side of FVH (number of left)a 6 (54
History of smokinga 6 (54
Hypertensiona 4 (36
Diabetes mellitusa 3 (27
History of VTEc 0
Hypercoagulable statec 0
Atrial fibrillationc 3 (27
Chronic renal insufficiencyc 1 (9%
Major postoperative complicationa 4 (36
Albuminb 2.7  0.7 (1.
Body mass indexb 24.8  4.3 (19
FVH, Femoral vein harvest; VTE, venous thromboembolism.
Continuous variablesb are expressed as mean standard deviation (range). P
and 2 analysisa or Fisher exact testc was used for categorical variables.(59%) in this series were still diagnosed within the first Fostoperative week. This high incidence of VTE in the
ancer patients argues for early routine postoperative ve-
ous ultrasound screening. After review of our data, we
ow screen all patients with cancer, despite symptoms, after
VH with a bilateral lower extremity venous duplex scan in
he second postoperative week. A subsequent venous ultra-
ound study is obtained at their first outpatient follow-up visit.
hile prolonged VTE prophylaxis is selectively used in some
atients with cancer, there is also a rationale for such an
pproach in a subset of patients after FVH procedure.
In this series, only selective patients were treated with
herapeutic anticoagulation. These included patients with a
re-existing indication for anticoagulation, a newly diag-
osed DVT proximal to the FVH site, a DVT in the limb
ontralateral to the FVH, and those diagnosed with PE.
ince all of these patients had cancer, they were treated with
rolonged LMWH as per the American College of Chest
hysicians Practice Guidelines.10 There were no complica-
ions noted with full anticoagulation in these patients, but
he overall numbers are small.
Given the high incidence of DVT in the FVH patients
ith cancer, one could argue that prophylactic anticoagu-
ation is ineffective and advocate therapeutic anticoagula-
ion or prophylactic inferior vena cava filter (IVC) place-
ent. However, both of these treatments are primarily
sed in patients with diagnosed DVTs to prevent death
rom PE, and only two PEs were diagnosed in this series.
rophylactic anticoagulation and/or IVC filter placement
as an unproven risk-benefit ratio in patients with FVH
ho have all undergone a major operation. At this time, we
herefore do not advocate routine therapeutic anticoagula-
ion or prophylactic IVC filter placement in patients with
ancer who have undergone, an FVH procedure, but we do
hink screening with routine scheduled venous ultrasound
ombined with extended VTE prophylaxis is a reasonable
nd low-risk alternative in cancer patients with a recent
n  11) Healed wound (n  47) P value
23 (49%) .62
60.4  13.3 (24-86) .04
25 (53%) .94
31 (66%) .48
16 (34%) .21
21 (46%) .62
10 (21%) .67
2 (4%) 1.00
2 (4%) 1.00
5 (10%) .15
2 (4%) .47
17 (36%) 1.00
) 2.9  0.8 (1.4-4.3) .13
.5) 26.0  6.1 (15.5-43.8) .39
s were obtained using independent variable t-test for continuous variablesbtion (
%)
-79)
%)
%)
%)
%)
%)
%)
)
%)
4-3.8
.2-31VH.
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Volume 56, Number 3 Dhanisetty et al 701Optimal treatment for DVT distal to the FVH site is
not well established. In our practice, most patients with
DVTs distal to the harvest site are not treated with thera-
peutic anticoagulation. It is not clear what the short-term
or long-term risk to the patient is from a DVT distal to the
FVH site. In their initial study, Clagett and associates
reported treatment of all DVTs distal to the FVH site to
avoid retrograde propagation.3 In another follow-up study,
DVTs confined to popliteal vein segment were not rou-
tinely treated with therapeutic anticoagulation. On long-
term follow-up of these patients, there was no difference in
venous morbidity when compared with patients without
postoperative DVT.4
Other infrequent but reported complications of FVH,
such as acute postoperative phlegmasia and compartment
syndrome requiring fasciotomy or amputation, were not
observed in our series. These complications seem to be
associated with more extensive harvest of the femoral vein
to include the popliteal vein. Preserving the popliteal vein
likely allows the leg to be drained by larger venous tribu-
taries between the popliteal vein and the profunda femoral
vein once the femoral vein has been harvested. In this series,
no segments of vein below the knee were harvested, and the
profunda femoris vein was preserved in all cases. Under
such circumstances, collaterals appear to be adequate to
drain the leg to a sufficient extent after FVH to minimize
the incidence of compartment syndrome.
Wound complications requiring surgical intervention
were observed in eight patients (14%). Surgical interven-
tion was primarily minor wound debridement and did not
affect hospital stay. No patient remained in the hospital
only for treatment of an FVH wound complication. One
patient did, however, require readmission for operative
wound debridement. Other than age, no other patient
factors, including BMI, anticoagulation, smoking history,
nutritional parameters, or malignancy, correlated with de-
velopment of wound complications.
The study has limitations. One is that prior to collect-
ing this data, we did not perform routine venous duplex
scans on all patients undergoing FVH. Consequently, the
total incidence of postoperative DVT is not known and may
be higher than reported, especially in the cancer patients.
However, it can be argued that even if the data underesti-
mate the problem of DVT in patients with FVH, the
documented incidence of DVT following FVH in patients
with cancer is sufficiently high to merit a policy of routine
postoperative venous duplex scanning in such patients.
Also, while the operative notes describe the location of the
distal transection site of the femoral vein, the exact length
of femoral vein harvested was not recorded. The extent of
vein harvested could potentially correlate with incidence of
DVT as well. Finally, as in virtually all studies of postoper-
ative DVT, while the administration of chemical prophy-
laxis can be confirmed, it is virtually impossible to retro-
spectively determine the extent to which patients were
compliant with mechanical VTE prophylaxis. One must
consider, given the data presented, whether a policy of
utilizing femoral vein for arterial or venous reconstructionsn patients with cancer is appropriate. We would argue that
t is for the following reasons. The femoral vein is a robust
onduit for an arterial or venous substitute and has minimal
raft-related complications. The lower extremities are easily
repped into the operative field, and the femoral vein can
e harvested without readjustment of the retractors for the
rimary operation. Harvest of limited portions of vein, as in
djuncts to most cancer procedures where arterial or venous
econstruction is required, is associated with minimal har-
est-related complications and no significant, and certainly
o debilitating, long-term complications. While DVT is
learly a problem, most DVTs occurred distal to the FVH.
VT occurring proximal to the harvest site may reflect a
ore generalized problem with cancer-associated hyperco-
gulable state, given the fact DVT in the opposite leg
ccurred nearly as often as DVT proximal to the FVH site.
inally, as noted above, patency rates are outstanding for
hese reconstructions even in patients with cancer.
ONCLUSIONS
FVH is associated with manageable short-term venous
orbidity and wound complications, with an increased
ncidence of DVT in patients with concurrent malignancy.
n patients without cancer, routine postoperative VTE
rophylaxis along with selective venous duplex scanning
uided by lower extremity symptoms should be adequate
o diagnose FVH-associated DVT. In contrast, patients
ith cancer have a significantly higher incidence of FVH-
ssociated venous thrombosis. In such patients, routine
enous duplex screening following FVH in association with
ore prolonged VTE prophylaxis seems reasonable.
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Dr E. John Harris, Jr (Stanford, Calif). Dr Quinones, Dr
Katz, members, and guests, I am happy to comment on this
well-presented paper by Dr Dhanisetty and the OHSU group. This
is a retrospective study generated by reviewing a prospective oper-
ative log, with the fem-pop vein harvest CPT code as the inclusion
criteria. As a retrospective review, many details of individual pro-
cedures just are not available, but general demographics are col-
lated and are not particularly enlightening. Cancer patients
undergoing mostly venous interposition grafting during por-
tomesenteric reconstruction following Whipple-type procedures
have a high rate (52%) of postoperative DVT in the harvest leg, but
harvest for arterial reconstruction for infection also led to ipsilateral
DVT, but the true rate remains elusive since prospective duplex
scanning of all harvest limbs is not part of the authors’ protocol,
and occurred in only 60% of the cohort, 28% of whom had a DVT.
Symptomatic legs only were scanned, with 100% of DVT showing
obstruction distal to the harvest, and 31% of these patients also
showing DVT proximal to the harvest. The overall rate of 28% for
symptomatic post harvest limb DVT should command our atten-
tion following femoral vein harvest, especially with PE noted in
3.4% of their patients. Prophylaxis against perioperative DVT
appeared uneven in this mixed population of cancer and noncancer
patients with varying scopes of procedures leading to variable risks
of postoperative bleeding if routine perioperative chemical prophy-
laxis would be employed identically in all patients. Wound compli-
cations occurred in 20% of patients, but most of these resolved with
minimal attention.
My questions are few, but ask in general, what have you
learned from this infrequent, roughly 10 patients per year experi-
ence? Do you perform your harvest before or concomitantly as
multiple teams with the index procedure? Were any vein harvests
performed while the patient was systemically anticoagulated, and if
yes, was their DVT rate lessened? Do you routinely now recom-
mend therapeutic rather than prophylactic heparin or heparinoid
dosing perioperatively in active cancer patients? If not, why not?
Based on the significant incidence of DVT in the harvest leg, do
you now routinely scan all harvest limbs perioperatively? Have youDr Ravi V. Dhanisetty. Thank you, Dr Harris, for your
omments.
Femoral vein is not required for most arterial and venous
econstructions, so the experience at any one center is limited. Our
ohort of 58 cases is comparable to previous series, the largest of
hich was 61 patients. Our study population, however, had a
ignificant number of patients with cancer; different from prior
eries. As a retrospective study, there are a number of limitations in
ur data, but it is clear femoral vein harvest has low short-term
orbidity in patients without cancer. Cancer patients, however,
learly have more trouble with venous thrombosis. Based on our
ata, patients with cancer, particularly pancreatic cancer, undergo-
ng femoral vein harvest would seem to have indications for routine
ostoperative screening for DVT and extended DVT prophylaxis.
Timing of the FVH depended on the index procedure. For
ost arterial reconstructions, the vein was harvested before or
oncomitantly with the procedure. In the setting of cancer, most of
he oncological resection was performed first, followed by vein
arvest and venous reconstruction.
None of the procedures were performed with the patient on
ystemic anticoagulation for the entire procedure. All patients
eceived full-dose heparin prior to the clamp placement and vascu-
ar reconstruction. The heparin was not routinely reversed.
For patients with cancer, we do now routinely scan all harvest
imbs postoperatively but do not believe, given the magnitude of
hese resections, that therapeutic anticoagulation is indicated im-
ediately postoperatively in all patients with cancer that undergo
emoral vein harvest. We do recommend prolonged pharmacologic
rophylaxis with LMWH and believe routine screening in this
opulation is indicated to diagnose DVT.
Most of the patients with cancer and femoral vein harvest in
ur series were undergoing pancreatic resection. There have been
eports of using alternate conduits in close proximity to a pancre-
tic anastomosis, but the possibility or bile or pancreatic leak in
lose proximity to the venous reconstruction leads us to prefer
utogenous conduit for these reconstructions. We have used cry-
vein for venous reconstruction in selected patients with cancer
here the possibility of contamination of the conduit is minimal.
